Combination therapy with InsB9-23 peptide immunization and CTLA4-IgG does not reverse diabetes in NOD mice

被引：2
|
作者：
Schneider, Darius A. [1 ]
Sarikonda, Ghanashyam [1 ]
von Herrath, Matthias G. [1 ]
机构：
[1] La Jolla Inst Allergy & Immunol, La Jolla, CA 92037 USA
来源：
CLINICAL IMMUNOLOGY | 2012年 / 142卷 / 03期
关键词：
AUTOIMMUNE; CD86;
D O I：
10.1016/j.clim.2011.12.005
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：402 / 403
页数：2
相关论文
共 15 条
  • [1] InsB9-23 Gene Transfer to Hepatocyte-Based Combined Therapy Abrogates Recurrence of Type 1 Diabetes After Islet Transplantation
    Russo, Fabio
    Citro, Antonio
    Squeri, Giorgia
    Sanvito, Francesca
    Monti, Paolo
    Gregori, Silvia
    Roncarolo, Maria Grazia
    Annoni, Andrea
    DIABETES, 2021, 70 (01) : 171 - 181
  • [2] Intranasal administration of insulin peptide B:9-23 protects NOD mice from diabetes
    Daniel, D
    Wegmann, DR
    ORAL TOLERANCE: MECHANISMS AND APPLICATIONS, 1996, 778 : 371 - 372
  • [3] Oleanolic Acid a Natural Plant Triterpenoid, Significantly Delays the Production of Autoantibodies and Autoreactive T Cells to Insulin/InsB(9-23) Peptide and Development of Diabetes in NOD Mice
    Angaswamy, N.
    Ramachandran, S.
    Tiriveedhi, V.
    Chapman, W.
    Mohanakumar, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 247 - 247
  • [4] InsB:9-23 peptide-based immunotherapy for type 1 diabetes; the immunization frequency and the state of the disease can alter the efficacy
    Fousteri, Georgia
    Dave, Amy
    Bresson, Damien
    Croft, Michael
    Chan, Jason
    Zheng, Yanan
    Whiting, Chan
    von Herrath, Matthias
    FASEB JOURNAL, 2008, 22
  • [5] InsB:9-23 peptide-based immunotherapy for type 1 diabetes;: The immunization route and the state of the disease can alter the efficacy
    Fousteri, Georgia
    Dave, Amy
    Bresson, Damien
    Croft, Michael
    von Herrath, Matthias
    CLINICAL IMMUNOLOGY, 2008, 127 : S105 - S106
  • [6] Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor reverses diabetes in NOD mice
    Suarez-Pinzon, Wilma L.
    Cembrowski, George S.
    Rabinovitch, Alex
    DIABETES, 2008, 57 : A444 - A444
  • [7] Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse
    Liu, E
    Morlyama, H
    Paronen, J
    Abiru, N
    Miao, DM
    Yu, LP
    Taylor, RM
    Eisenbarth, GS
    JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) : 213 - 219
  • [8] Combination of Neurogenin3 Gene Therapy With an Anti-TCR mAb Reverse Established Type 1 Diabetes in NOD Mice.
    Xie, A.
    Li, R.
    Li, X.
    Chan, L.
    Chen, W.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 359 - 359
  • [9] Combination of Neurogenin3 Gene Therapy With an Anti-TCR mAb Reverse Established Type 1 Diabetes in NOD Mice.
    Xie, A.
    Li, R.
    Li, X.
    Chan, L.
    Chen, W.
    TRANSPLANTATION, 2014, 98 : 359 - 359
  • [10] Induction of autoantibodies to native insulin in normal and NOD derived mice following immunization with the immunodominant self-B-chain insulin peptide B:9-23
    Abiru, N
    Yu, LP
    Wegmann, D
    Eisenbarth, GS
    DIABETES, 2000, 49 : A232 - A233
12